US1011371077
© BusinessWire
09.02.2026
BSX
LISTED
NYSE
Securities Fraud Investigation Into Boston Scientific Corporation (BSX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR W...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2026
BSX
LISTED
NYSE
Boston Scientific Corporation (BSX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BOSTON SCIENTIFIC CORPORATION (BSX), CONTACT THE LAW OFFICES OF HO...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2026
BSX
LISTED
NYSE
Securities Fraud Investigation Into Boston Scientific Corporation (BSX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON BOSTON SCIENTIFIC CORPORATION (BSX), CLICK HERE TO INQUIRE ABOUT P...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
04.02.2026
BSX
LISTED
NYSE
Boston Scientific announces results for fourth quarter and full year 2025
News Preview
MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP n...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© PR Newswire
15.01.2026
BSX
LISTED
NYSE
Boston Scientific announces agreement to acquire Penumbra, Inc.
News Preview
Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseasesProvides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacenciesConference call at 8:00 a.m. ET to discuss details of the transactionMARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /P...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
BSX
LISTED
NYSE
Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation
News Preview
Acquisition to expand urology offerings for people living with overactive bladderMARLBOROUGH, Mass., Jan. 12, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on the development...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2026
BSX
LISTED
NYSE
Boston Scientific announces participation in the J.P. Morgan Healthcare Conference and conference call discussing fourth quarter and full year 2025 results
News Preview
MARLBOROUGH, Mass., Jan. 2, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026, in San Francisco. Mike Mahoney, chairman and chief executive officer, Jon Monson, executive vice president and chief financial officer, and Ken Stein, M.D.,...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
BSX
LISTED
NYSE
Boston Scientific announces upcoming investor conference schedule
News Preview
MARLBOROUGH, Mass., Nov. 3, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.
On November 18,...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
BSX
LISTED
NYSE
Boston Scientific announces results for third quarter 2025
News Preview
MARLBOROUGH, Mass., Oct. 22, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational1 basis and 15.3 percent on an organic2 basis, all compared to the prior year...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
BSX
LISTED
NYSE
Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.
News Preview
Acquisition to expand the neuromodulation offerings for people living with chronic pain
MARLBOROUGH, Mass., Oct. 17, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Nalu Medical...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
BSX
LISTED
NYSE
Boston Scientific announces 2025 Investor Day meeting and conference call discussing third quarter 2025 results
News Preview
MARLBOROUGH, Mass., Sept. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Tuesday, September 30, 2025, beginning at 8:30 a.m. ET....
Themefolio
Profiler
Peergroup
© PR Newswire
23.07.2025
BSX
LISTED
NYSE
Boston Scientific announces results for second quarter 2025
News Preview
MARLBOROUGH, Mass., July 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reported basis, 21.6 percent on an operational1 basis and 17.4 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
07.07.2025
BSX
LISTED
NYSE
Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System
News Preview
The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation
MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARA...
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2025
BSX
LISTED
NYSE
Boston Scientific announces conference call discussing second quarter 2025 results
News Preview
MARLBOROUGH, Mass., July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and...
Themefolio
Profiler
Peergroup
© PR Newswire
01.05.2025
BSX
LISTED
NYSE
Boston Scientific announces upcoming investor conference schedule
News Preview
MARLBOROUGH, Mass., May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May.
On May 13, 2025, Dan Brennan, executive vice president and chief financial offi...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
BSX
LISTED
NYSE
Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints
News Preview
Trial achieves positive results in the treatment of persistent atrial fibrillation
MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE™ Puls...
Themefolio
Profiler
Peergroup
© PR Newswire
23.04.2025
BSX
LISTED
NYSE
Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan
News Preview
MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to retire following nearly 30 successful years with the company. Brennan will transition out of the chief financial officer position at the end of June and...
Themefolio
Profiler
Peergroup
© PR Newswire
23.04.2025
BSX
LISTED
NYSE
Boston Scientific announces results for first quarter 2025
News Preview
MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
BSX
LISTED
NYSE
Boston Scientific announces conference call discussing first quarter 2025 results
News Preview
MARLBOROUGH, Mass., April 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2025, on Wednesday, April 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer,...
Themefolio
Profiler
Peergroup
© PR Newswire
03.03.2025
BSX
LISTED
NYSE
Boston Scientific announces agreement to acquire SoniVie Ltd.
News Preview
Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension
MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical d...
Themefolio
Profiler
Peergroup
© PR Newswire
26.02.2025
BSX
LISTED
NYSE
Boston Scientific announces completion of €1.5 billion offering of senior notes
News Preview
MARLBOROUGH, Mass., Feb. 26, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V. ("AMS Europe"), its wholly owned finance subsidiary, has completed a public offering of €850,000,000 aggregate principal amount of 3.000% notes due 2031 and €650,000,000 aggregate pr...
Themefolio
Profiler
Peergroup
© PR Newswire
22.02.2025
BSX
LISTED
NYSE
Boston Scientific announces pricing of €1.5 billion of senior notes
News Preview
MARLBOROUGH, Mass., Feb. 21, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V. ("AMS Europe"), its wholly owned finance subsidiary, has priced a public offering of €850,000,000 aggregate principal amount of 3.000% notes due 2031 and €650,000,000 aggregate princ...
Themefolio
Profiler
Peergroup
© PR Newswire
19.02.2025
BSX
LISTED
NYSE
Boston Scientific to participate in TD Cowen's 45th Annual Health Care Conference
News Preview
MARLBOROUGH, Mass., Feb. 19, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025.
Dan Brennan, executive vice president and chie...
Themefolio
Profiler
Peergroup
© PR Newswire
05.02.2025
BSX
LISTED
NYSE
Boston Scientific announces results for fourth quarter and full year 2024
News Preview
MARLBOROUGH, Mass., Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational1 basis and 19.5 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2025
BSX
LISTED
NYSE
Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
News Preview
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System
Sub-analysis from OPTION clinical trial highlights consistent safety and efficacy outcomes with the WATCHMAN FLX™ Left Atrial Appendage...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
BSX
LISTED
NYSE
Boston Scientific Announces Agreement to Acquire Bolt Medical, Inc.
News Preview
Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company's strategy to address coronary and peripheral disease
MARLBOROUGH, Mass., Jan. 8, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquir...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
BSX
LISTED
NYSE
Boston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results
News Preview
MARLBOROUGH, Mass., Jan. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, in San Francisco. Mike Mahoney, chairman and chief executive officer, will present at approximately 5:15 p.m. PT / 8:15 p.m. ET. Mahoney will be joined by Dan...
Themefolio
Profiler
Peergroup
© PR Newswire
25.11.2024
BSX
LISTED
NYSE
Boston Scientific Announces Agreement to Acquire Intera Oncology® Inc.
News Preview
Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases
MARLBOROUGH, Mass., Nov. 25, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Intera Oncology® Inc., a privately held medical device company that...
Themefolio
Profiler
Peergroup
© PR Newswire
16.11.2024
BSX
LISTED
NYSE
Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial
News Preview
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation
MARLBOROUGH, Mass. and CHICAGO, Nov. 16, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive three-year primary endpoint results from the OPTION...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2024
BSX
LISTED
NYSE
Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference
News Preview
MARLBOROUGH, Mass., Nov. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024.
Nick Spadea-Anello, president, Electrophysiolog...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
BSX
LISTED
NYSE
Boston Scientific Announces Agreement to Acquire Cortex, Inc.
News Preview
Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation
MARLBOROUGH, Mass., Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately hel...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
BSX
LISTED
NYSE
ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024
News Preview
MARLBOROUGH, Mass. and WASHINGTON, Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2™ Aortic Valve System in the treatment of patients with severe, symptomatic aortic stenosis at low, intermediate, high and...
Themefolio
Profiler
Peergroup
© PR Newswire
23.10.2024
BSX
LISTED
NYSE
Boston Scientific Announces Results for Third Quarter 2024
News Preview
MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2024
BSX
LISTED
NYSE
Boston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System
News Preview
New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation
MARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the navigation-enabl...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2024
BSX
LISTED
NYSE
Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results
News Preview
-Company to also host virtual webcast with a cardiology business update-
MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. T...
Themefolio
Profiler
Peergroup
© PR Newswire
27.09.2024
BSX
LISTED
NYSE
Boston Scientific Receives Japanese Regulatory Approval for the FARAPULSE™ Pulsed Field Ablation System
News Preview
MARLBOROUGH, Mass., Sept. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System, which is indicated for the isolation of pulmonary veins in the treatment of parox...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2024
BSX
LISTED
NYSE
Boston Scientific Receives FDA Approval for Expanded Indication of INGEVITY™+ Pacing Leads to Include Conduction System Pacing of the Left Bundle Branch Area
News Preview
MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the indication for current-generation INGEVITY™+ Pacing Leads – thin wires placed inside the heart and connected to an implantable device – to include conduction system pacing (CSP) a...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
BSX
LISTED
NYSE
Boston Scientific Obtains CE Mark for ACURATE Prime™ Aortic Valve System
News Preview
MARLBOROUGH, Mass., Aug. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has obtained CE mark for the ACURATE Prime™ Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology in the company's structural heart portfolio. The ACURATE Prime valve system is designed with several fea...
Themefolio
Profiler
Peergroup
© PR Newswire
13.08.2024
BSX
LISTED
NYSE
Boston Scientific to Participate in Wells Fargo's 2024 Healthcare Conference
News Preview
MARLBOROUGH, Mass., Aug. 13, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 2024 Healthcare Conference on Wednesday, September 4, 2024.
Mike Mahoney, chairman and chief executive of...
Themefolio
Profiler
Peergroup
© PR Newswire
24.07.2024
BSX
LISTED
NYSE
Boston Scientific Announces Results for Second Quarter 2024
News Preview
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP...
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2024
BSX
LISTED
NYSE
Boston Scientific Announces Conference Call Discussing Second Quarter 2024 Results
News Preview
MARLBOROUGH, Mass., July 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2024, on Wednesday, July 24, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, an...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
